公开(公告)号：US20090069313A1

公开(公告)日：2009-03-12

申请号：US11896902

申请日：2007-09-06

申请人： Debendranath Dey ,  Gajendra Singh ,  Partha Neogi ,  Uma Ramachandran ,  Chithra Santhanagopalan

发明人： Debendranath Dey ,  Gajendra Singh ,  Partha Neogi ,  Uma Ramachandran ,  Chithra Santhanagopalan

IPC分类号： A61K31/5377 ,  C07D277/16 ,  A61K31/426 ,  C07D209/34 ,  A61P25/24 ,  A61P25/32 ,  A61P25/08 ,  A61P25/00 ,  A61P25/34 ,  A61P25/28 ,  A61K31/404 ,  C07D413/12 ,  A61K31/422

CPC分类号： C07D277/36 ,  C07D209/34 ,  C07D277/34 ,  C07D413/12 ,  C07D417/12

摘要： The present invention provides a new medical use for the compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, as MAO-A inhibitors. Also included is a method for prophylaxis and treatment of mental disorders such as depression, in a mammal, comprising administering an effective amount of a compound of formula (I). These compounds are also effective in treating a disease, condition or disorder such as weight loss, obesity, bulimia, depression, bipolar disorders, psychoses, schizophrenia, behaviors, alcoholism, tobacco abuse, memory loss, Alzheimer's disease, dementia of aging, seizure disorders, epilepsy, attention deficit disorder, and Parkinson's disease, which is modulated by a cannabinoid receptor antagonist.

摘要翻译： 本发明提供了作为MAO-A抑制剂的式（I）化合物，其衍生物，类似物，互变异构形式，立体异构体，多晶型物，水合物，溶剂合物，药学上可接受的盐和组合物，其代谢物和前药的新医学用途 。 还包括在哺乳动物中预防和治疗精神障碍如抑郁症的方法，包括施用有效量的式（I）化合物。 这些化合物在治疗疾病，病症或病症如体重减轻，肥胖，贪食症，抑郁症，双相性精神障碍，精神病，精神分裂症，行为，酒精中毒，吸烟，记忆丧失，阿尔茨海默病，老年痴呆，癫痫发作障碍 ，癫痫，注意力缺陷障碍和由大麻素受体拮抗剂调节的帕金森病。